Evidence map›Paper›PMID 37370121›Full record

Observational studyRespiratory research2023

Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational study.

Peter Kamstrup, Pradeesh Sivapalan, Christian Rønn, Ema Rastoder, Daniel Modin, Anna Kjaer Kristensen, Elisabeth Bendstrup, Rikke Sørensen, Tor Biering-Sørensen, Charlotte Suppli Ulrik and 2 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Peter KamstrupSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Pradeesh SivapalanSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Christian RønnSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Ema RastoderSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Daniel ModinDepartment of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Anna Kjaer KristensenSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Elisabeth BendstrupDepartment Respiratory Disease and Allergy, Aarhus University Hospital, Aarhus, 8000, Denmark.
Rikke SørensenDepartment of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 2100, Denmark.
Tor Biering-SørensenDepartment of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark.
Charlotte Suppli UlrikDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, 2200, Denmark.
Jørgen VestboThe North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M13 9PL, UK.
Jens-Ulrik JensenSection of Respiratory Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, 2900, Denmark. jens.ulrik.jensen@regionh.dk.
Gentofte Hospital · DKUniversity of Copenhagen · DKAarhus University Hospital · DKCopenhagen University Hospital · DKManchester Academic Health Science Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with chronic obstructive pulmonary disease (COPD) have a high incidence of cardiovascular disease including thromboembolisms. Fibrin degradation products, like D-dimer, have been associated with death from all causes in healthy individuals and COPD patients. We aimed to determine the (i) association between D-dimer levels and all-cause mortality and time being alive and out of a hospital, (ii) possible modifying effect of anticoagulant treatment,, and (iii) distribution of D-dimer in patients with moderate to severe COPD.

methodsResults of routinely measured stable phase D-dimer samples from COPD-outpatients at Copenhagen University Hospital - Herlev and Gentofte, COPD-outpatient clinic were collected using the Danish registries. These were used to examine whether COPD-patients with a D-dimer level in the upper quartile, had a higher risk of death from all causes within 365 days.

resultsIn the unadjusted Cox proportional hazards regression we found an association between high D-dimer and all-cause mortality: Hazard ratio (HR): 2.3 (95% Confidence Interval (CI) 1.1-4.7). In the fully adjusted regression, the HR was 1.8 (CI 0.8-3.9). We did not find any interaction between D-dimer and anticoagulant or antiplatelet therapy. For the secondary outcome, proportion of days alive and out of hospital in 365 days (pDAOH), the unadjusted multiple linear regression had an association between high D-dimer level and pDAOH: -2.7% points (pp) (CI -3.9 pp - -1.5 pp), which was attenuated to -1,7pp (-2.9pp - -0.4pp) in the fully adjusted regression.

conclusionsIn patients with moderate to severe COPD, patients with a high level of D-dimer were more likely to die; however, the signal was not strong in the adjusted analyses and our results do not support unselected risk stratification with D-dimer in COPD-outpatients.

Indexed as

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveAnticoagulantsFibrin Fibrinogen Degradation ProductsHumansProspective StudiesAnticoagulantsFibrin Fibrinogen Degradation ProductsAll-cause mortalityBiomarkerCohortCOPDD-dimer

Identifiers

PMID37370121
PMCPMC10294503
OpenAlexW4382281732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.